A Risk-Benefit Assessment of Oxytocics in Obstetric Practice

被引:0
|
作者
Matthias Winkler
Werner Rath
机构
[1] Technical University,Department for Obstetrics and Gynecology, University Hospital
来源
Drug Safety | 1999年 / 20卷
关键词
Adis International Limited; Oxytocin; Misoprostol; Ergot Alkaloid; Uterine Rupture;
D O I
暂无
中图分类号
学科分类号
摘要
Substances that stimulate contractions of the myometrium have found wide applications in present day obstetrics. Above all, fully synthetic, uterus-selective Prostaglandin analogues are used for preoperative priming of the cervix for termination of pregnancies in the first trimester as well as for the induction of abortions in the second trimester and have proved to have a much higher efficacy than Oxytocin. Because of the pharmacological synergism of their cervix ripening and myometrium stimulating activities, the local use of natural Prostaglandin E2 preparations (used intracervically as a gel or vaginally as a gel or as a tablet) is unequivocally superior to use of Oxytocin with its almost exclusive contraction stimulating activity for induction of labour, especially for women with an unripe cervix. In women with a ripe cervix, Oxytocin and Prostaglandins are equally effective with Oxytocin having the major advantage of its better controllability on continuous intravenous infusion (plasma elimination half-life of 10 minutes).
引用
收藏
页码:323 / 345
页数:22
相关论文
共 50 条
  • [1] A risk-benefit assessment of oxytocics in obstetric practice
    Winkler, M
    Rath, W
    DRUG SAFETY, 1999, 20 (04) : 323 - 345
  • [2] Quantifiable risk-benefit assessment of micronutrients: From theory to practice
    Krul, Lisette
    Kremer, Bas H. A.
    Luijckx, Niels B. Lucas
    Leeman, Winfried R.
    CRITICAL REVIEWS IN FOOD SCIENCE AND NUTRITION, 2017, 57 (17) : 3729 - 3746
  • [3] Risk-Benefit Assessment of Foods
    Assuncao, R.
    Pires, S. M.
    Nauta, M.
    EFSA JOURNAL, 2019, 17
  • [4] A Risk-Benefit Assessment of Antileukotrienes in Asthma
    Lewis J. Smith
    Drug Safety, 1998, 19 : 205 - 218
  • [5] A Risk-Benefit Assessment of Amifostine in Cytoprotection
    May Mabro
    Sandrine Faivre
    Eric Raymond
    Drug Safety, 1999, 21 : 367 - 387
  • [6] A RISK-BENEFIT ASSESSMENT OF RISPERIDONE IN SCHIZOPHRENIA
    CURTIS, VA
    KERWIN, RW
    DRUG SAFETY, 1995, 12 (02) : 139 - 145
  • [7] Risk-benefit ratio or risk-benefit nonsense?
    Ernst, E
    Resch, KL
    JOURNAL OF CLINICAL EPIDEMIOLOGY, 1996, 49 (10) : 1203 - 1204
  • [8] THE RISK-BENEFIT ASSESSMENT OF ANTIDEPRESSANT DRUGS
    HENRY, JA
    MARTIN, AJ
    MEDICAL TOXICOLOGY AND ADVERSE DRUG EXPERIENCE, 1987, 2 (06): : 445 - 462
  • [9] A RISK-BENEFIT ASSESSMENT OF TACROLIMUS IN TRANSPLANTATION
    WINKLER, M
    CHRISTIANS, U
    DRUG SAFETY, 1995, 12 (05) : 348 - 357
  • [10] A RISK-BENEFIT ASSESSMENT OF TAMOXIFEN THERAPY
    CATHERINO, WH
    JORDAN, VC
    DRUG SAFETY, 1993, 8 (05) : 381 - 397